NVUS vs. PHIO, LGVN, PHAS, NBY, REVB, ARDS, BCEL, ARAV, CWBR, and BPTS
Should you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Phio Pharmaceuticals (PHIO), Longeveron (LGVN), PhaseBio Pharmaceuticals (PHAS), NovaBay Pharmaceuticals (NBY), Revelation Biosciences (REVB), Aridis Pharmaceuticals (ARDS), Atreca (BCEL), Aravive (ARAV), CohBar (CWBR), and Biophytis (BPTS). These companies are all part of the "medical" sector.
Phio Pharmaceuticals (NASDAQ:PHIO) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Phio Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.
Phio Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 426.32%. Given Novus Therapeutics' higher probable upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Novus Therapeutics.
Novus Therapeutics received 216 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 66.84% of users gave Novus Therapeutics an outperform vote while only 63.16% of users gave Phio Pharmaceuticals an outperform vote.
Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phio Pharmaceuticals had 15 more articles in the media than Novus Therapeutics. MarketBeat recorded 15 mentions for Phio Pharmaceuticals and 0 mentions for Novus Therapeutics. Novus Therapeutics' average media sentiment score of 0.54 beat Phio Pharmaceuticals' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.
Novus Therapeutics' return on equity of -123.19% beat Phio Pharmaceuticals' return on equity.
57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Phio Pharmaceuticals beats Novus Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Novus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novus Therapeutics Competitors List
Related Companies and Tools
